- Home
- MOLN vs OPRX Comparison
MOLN vs OPRX Comparison
Compare MOLN & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | OPRX |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Business Services |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.0M | 115.4M |
| IPO Year | 2021 | 2008 |
Fundamental Metrics
Financial Performance| Metric | MOLN | OPRX |
|---|---|---|
| Price | $4.33 | $6.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.38 | ★ $16.67 |
| AVG Volume (30 Days) | 3.6K | ★ 483.1K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 124.55 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $109,429,000.00 |
| Revenue This Year | N/A | $3.88 |
| Revenue Next Year | $374.07 | $8.49 |
| P/E Ratio | ★ N/A | $24.07 |
| Revenue Growth | N/A | ★ 18.78 |
| 52 Week Low | $3.36 | $5.54 |
| 52 Week High | $5.36 | $22.25 |
Technical Indicators
Market Signals| Indicator | MOLN | OPRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.44 | 38.53 |
| Support Level | $4.04 | $5.89 |
| Resistance Level | $4.51 | $7.47 |
| Average True Range (ATR) | 0.19 | 0.49 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 61.43 | 13.07 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.